Core Scientific (CORZ) EBITDA (2020 - 2026)

Core Scientific has disclosed EBITDA across 7 years of filings, most recently posting -$78.5 million for Q2 2026.

• In Q2 2026, EBITDA fell 198.54% year-over-year to -$78.5 million; the TTM figure through Jun 2026 stood at -$561.2 million (down 211.87% YoY), while the FY2025 annual figure was -$245.6 million, down 72.87% from the prior year.
• EBITDA came in at -$78.5 million for Q2 2026 at Core Scientific, up from -$310.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $55.2 million in Q1 2024 to a low of -$1.0 billion in Q2 2022.
• Average EBITDA over 5 years is -$159.8 million, with a median of -$50.9 million recorded in 2025.
• Year-over-year, EBITDA sank 8489.92% in 2022 and soared 626.48% in 2024.
• Over 5 years, EBITDA stood at -$636.1 million in 2022, then jumped by 100.62% to $3.9 million in 2023, then tumbled by 1762.2% to -$65.4 million in 2024, then sank by 79.65% to -$117.5 million in 2025, then surged by 33.2% to -$78.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$78.5 million in Q2 2026, -$310.4 million in Q1 2026, and -$117.5 million in Q4 2025.